Guardant Health, Inc.
NASDAQ:GHMedical - Diagnostics & Research
+$2.67 today
- Market cap
- $19.64B
- Beta
- 1.62
- P/E (TTM)
- -39.9
- EPS (TTM)
- -$3.30
Volume 1.50M
Average 2.21M
GH Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Guardant Health, Inc.NASDAQ: GH
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $62.44M rose 45.8% year over year, ahead of the +32.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.
Context
- Stock-based compensation amounted to 16.9% of revenue in FY2025, down 2.1 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +45.8% holds above the trailing-twelve-month pace of +32.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 166.22M USD
- Year-over-year change
- +18.4%
- 4-year CAGR
- +2.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 166.22M | +18.4% |
| FY2024 | 2024-12-31 | 140.41M | +54.7% |
| FY2023 | 2023-12-31 | 90.76M | -4.1% |
| FY2022 | 2022-12-31 | 94.69M | -37.5% |
| FY2021 | 2021-12-31 | 151.45M | — |
Stock-Based Compensation vs competitors
How GH compares with its peers on the latest reported figures
- GH's LTM Sep 2026 stock-based compensation of $210.96M is the 2nd largest of the 10 companies compared; the peer median is $28.16M.
- Its year-over-year change of +32.4% is the highest of 9, against a peer median of -21.5%.
- Stock-based compensation amounts to 16.5% of revenue for GH, versus a peer median of 6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $381.42M | +21.6% | +32.5% | 14.1% | |
| LTM Sep 2026 | $210.96M | +32.4% | +20.6% | 16.5% | |
| LTM Mar 2026 | $44.49M | -8.9% | +8.1% | 13.1% | |
| LTM Mar 2026 | $32.2M | -31.9% | -2.6% | 3.9% | |
| LTM Mar 2026 | $29.03M | -33.3% | +6.6% | 9.1% | |
| LTM Jun 2026 | $28.16M | -29.2% | +18.8% | 3.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $25.54M | — | — | 6.4% |
| LTM Mar 2026 | $9.76M | -4.5% | -21.4% | 15.1% | |
| LTM Jun 2026 | $5.97M | -90.3% | -8.4% | 3.6% | |
| LTM Mar 2026 | $4.28M | -13.8% | -11.4% | 4.5% | |
| Peer median (excluding GH) | $28.16M | -21.5% | +2.0% | 6.4% | |
Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (384.77M) | (654.59M) | (479.45M) | (436.37M) | (416.28M) |
| Depreciation & Amortization | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 151.45M | 94.69M | 90.76M | 140.41M | 166.22M |
| Change in Working Capital | (40.47M) | 61.56M | 53.84M | (60.86M) | (14.43M) |
| Accounts Receivables | (44.35M) | 375K | 8.38M | (21.39M) | (28.18M) |
| Inventory | (7.96M) | (20.93M) | (10.35M) | (9.14M) | (14.79M) |
| Accounts Payables | 8.64M | 60.33M | 0 | 0 | 0 |
| Other Working Capital | 3.2M | 21.79M | 55.81M | (30.34M) | 28.54M |
| Other Non-Cash Items | 42.5M | 152.91M | (33.01M) | 74.58M | 39.99M |
| Operating Cash Flow | (209.02M) | (309.46M) | (324.98M) | (239.86M) | (184.76M) |
| Capital Expenditures | (75.04M) | (77.46M) | (20.49M) | (35.09M) | (48.31M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (58.99M) |
| Purchases of Investments | (940.23M) | (327.72M) | (635.5M) | (314.82M) | (827.23M) |
| Sales of Investments | 952.11M | 555M | 1.5B | 88.6M | 307.32M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (63.16M) | 149.82M | 840.25M | (261.31M) | (627.2M) |
| Debt Repayment | (146K) | (71K) | 0 | 0 | 402.5M |
| Common Stock Issued | 0 | 0 | 493.12M | 14.84M | 377.81M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (45.01M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (66.68M) | (189.02M) | (15.74M) | (15.83M) | (64.17M) |
| Financing Cash Flow | (66.82M) | (189.09M) | 477.38M | (996K) | 671.13M |
| Effect of Forex Changes | (1.69M) | (1.6M) | (911K) | (1.77M) | 491K |
| Net Change in Cash | (340.69M) | (350.34M) | 991.74M | (503.93M) | (140.34M) |
| Free Cash Flow | (284.05M) | (386.92M) | (345.46M) | (274.94M) | (233.07M) |
Guardant Health, Inc.
NASDAQ:GH
Intrinsic Alpha fair value
Locked
Current Price
$145.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.